Progenics Pharmaceuticals Inc (PGNX) SEC Filing 8-K Material Event for the period ending Monday, May 18, 2020

Progenics Pharmaceuticals Inc

CIK: 835887 Ticker: PGNX

View differences made from one to another to evaluate Progenics Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Progenics Pharmaceuticals Inc.


Assess how Progenics Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Progenics Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Progenics Pharmaceuticals Inc provided additional information to their SEC Filing as exhibits

Ticker: PGNX
CIK: 835887
Form Type: 8-K Corporate News
Accession Number: 0001437749-20-011152
Submitted to the SEC: Mon May 18 2020 4:01:47 PM EST
Accepted by the SEC: Mon May 18 2020
Period: Monday, May 18, 2020
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: